Goldman Sachs Boosts Biogen Stock Target Amid New Alzheimer's Strategy
Goldman Sachs has updated its price target for Biogen, indicating a positive outlook on the company's innovative approach to Alzheimer's treatment.
Editorial Staff about 2 months ago